U.S. Ends Funding For Moderna's Influenza Vaccine; Moderna Explores Alternatives For H5 Program

The U.S. Department of Health and Human Services (HHS) is terminating approximately $590 million in funding for Moderna's late-stage development of pre-pandemic influenza vaccines, citing scientific and ethical concerns after a rigorous review. Moderna, which received $176 million from HHS in 2024, will explore alternative development paths for its H5 program, despite positive interim Phase 1/2 data for its mRNA-1018 vaccine candidate targeting the H5 avian influenza virus subtype. Moderna CEO Stéphane Bancel acknowledged the uncertainty caused by the funding termination but highlighted the robust immune response and safety profile observed in the study.

Analysis

The U.S. Department of Health and Human Services (HHS) has notified Moderna (MRNA) of its decision to terminate funding intended for the late-stage development of its pre-pandemic influenza vaccines, specifically the H5 program, and the associated right to purchase. This decision, impacting a previously announced potential funding of approximately $590 million, of which Moderna had received $176 million in 2024 for its vaccine efforts, was based on an HHS review concluding that further investment was "neither scientifically nor ethically justifiable." This development introduces significant uncertainty for the H5 program, as acknowledged by Moderna's CEO Stéphane Bancel. Despite this setback, Moderna recently announced positive interim Phase 1/2 clinical data for its mRNA-1018 H5 avian flu vaccine candidate, which demonstrated a robust immune response and was generally well-tolerated in approximately 300 healthy adults. The company has stated it will explore alternative pathways for the program's advancement, consistent with its strategic commitment to pandemic preparedness, though the loss of HHS support for late-stage development presents a material challenge and a negative signal for this specific vaccine initiative.

Key Decisions for Investors

• Investors should reassess the projected timeline and commercial viability of Moderna's H5 influenza vaccine program given the HHS funding termination and the cited scientific and ethical concerns, despite positive early-stage clinical results.
• Closely monitor Moderna's disclosures regarding alternative funding mechanisms or strategic partnerships for the late-stage development of the H5 program, as these will be critical indicators for its future progression.
• Consider the increased risk profile and potential delays for the H5 vaccine's path to market, and weigh this against the company's broader pipeline and financial resilience when evaluating MRNA's stock.